

Application No. 10/526,849  
Paper dated October 28, 2005  
Attorney Docket No. 0470-050737

JCN4 Rec'd PCT/PTO 31 OCT 2005

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/526,849  
Applicants : Rene Frank Van Der Linden et al.  
Received : March 4, 2005  
Title : USE OF A SRI AND VITAMINE B6 FOR  
THE TREATMENT OF NEUROLOGICAL  
AND MENTAL DISORDERS  
Group Art Unit : Not yet assigned.  
Examiner : Not yet assigned.  
Customer No. : 28289

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 CFR §§ 1.56, 1.97, and 1.98, the Applicants hereby submit this Information Disclosure Statement together with a completed Form PTO/SB/08A and one copy of the references listed thereon except U.S. patents.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 28, 2005.

Helen Gerace  
(Name of Person Mailing Paper)

*Helen Gerace* October 28, 2005  
Signature Date


Application No. 10/526,849  
 Paper dated October 28, 2005  
 Attorney Docket No. 0470-050737

This application is the United States national phase of PCT Application No. PCT/NL2003/000622. The International Search Report, dated November 28, 2003, for the underlying PCT Application identified the references listed on Form PTO/SB/08A. A copy of the International Search Report is enclosed for the Examiner's convenience.


Pursuant to 37 C.F.R. § 1.97(b)3, no fee is believed to be due for the submission of this Information Disclosure Statement, as it is being submitted before the mailing date of a first Office Action on the merits. Nevertheless, the Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

THE WEBB LAW FIRM

By 

William H. Logsdon  
 Registration No. 22,132  
 Attorney for Applicants  
 700 Koppers Building  
 436 Seventh Avenue  
 Pittsburgh, PA 15219-1818  
 Telephone: 412-471-8815  
 Facsimile: 412-471-4094  
 E-mail: [webblaw@webblaw.com](mailto:webblaw@webblaw.com)



Substitute for form 1449A/PTO

*(Use as many sheets as necessary)*

**Complete if Known**

<b>Application Number</b>	10/526,849
<b>Received Date</b>	March 4, 2005
<b>First Named Inventor</b>	Rene Frank Van Der Linden
<b>Art Unit</b>	Not yet assigned.
<b>Examiner Name</b>	Not yet assigned.
<b>Attorney Docket Number</b>	0470-050737

Sheet

1

of

2

Attorney Docket Number

0470-050737

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	4.	EP 1 266 659 A	12/18/2002	PANTARHEI BIOSCIENCE B V		


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

{W0225243.1}



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

Application Number	10/526,849
Filing Date	March 4, 2005
First Named Inventor	Rene Frank Van Der Linden
Art Unit	Not yet assigned.
Examiner Name	Not yet assigned.
Attorney Docket Number	0470-050737

Sheet	1	of	2
-------	---	----	---

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	5.	CLINICAL CAREGROUP: Selective serotonin reuptake inhibitors (SSRI) Retrieved from the Internet: URL: clinical.caregroup.org/a...actions/Dr_uG_Classes/SSRI's.htm, 09/21/2001, pages 1-2	
	6.	ERIKSSON E ET AL: Diagnosis and Treatment of Premenstrual Dysphoria, Journal of Clinical Psychiatry, XX, XX, vol. 63, no. Suppl. 7, 2002, pages 16-23	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.